Labels

Monday, February 22, 2010

Big upset at the Olympics last night, but before we get to that there is of course the latest industry news. Until you can get biopharma wrap-ups at ESPN, we'll keep on keepin' on.

While you were pondering reconciliation ...

A bad weekend for GSK (after a tough week): a report released by Sens Baucus and Grassley that notes FDA reviewers' 2008 recommendation that diabetes drug Avandia get pulled because it causes "500 additional heart attacks per month" was the subject of about six thousand articles. Oh look, here's one.

The NYTimes begins a new three-part series, Target Cancer, with a moving, in-depth look at oncologist's attempts to push forward new targeted therapies for melanoma: earlier failures and hopefully a success story of Plexxikon/Roche's PLX4032.

It's almost time for that health care summit at the White House. Reuters reports on the administration's updated proposals, expected out on Monday. Here's a Bloomberg piece on a proposal to limit insurance price hikes.

No comments:

About This Blog

Welcome to The IN VIVO Blog, home of daily commentary on recent developments in biopharmaceutical business development, R&D, financing, marketing, and policy. Join us for discussion in the comments, or contact us via email.